抗干扰素-β中和活性并非完全由抗体介导。
Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
作者信息
Gilli Francesca, Marnetto Fabiana, Caldano Marzia, Valentino Paola, Granieri Letizia, Di Sapio Alessia, Capobianco Marco, Sala Arianna, Malucchi Simona, Kappos Ludwig, Lindberg Raija L P, Bertolotto Antonio
机构信息
Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy.
出版信息
J Neuroimmunol. 2007 Dec;192(1-2):198-205. doi: 10.1016/j.jneuroim.2007.09.025. Epub 2007 Oct 22.
Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.
许多接受β-干扰素（IFNβ）治疗的多发性硬化症（MS）患者会产生抗IFNβ抗体（BAbs），这些抗体可干扰注射的细胞因子的体外和体内生物活性。本研究的目的是关联这些指标。在256名登记患者中，11名（4.3%）在体外显示出对IFNβ活性的显著抑制，但未检测到可测量的BAbs。总体而言，这些患者中有9/11（82%）的体内生物活性受到抑制。少数接受IFNβ治疗的患者具有非抗体介导的中和活性，其在体外和体内均竞争性抑制生物活性。
Zotero 插件